Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Opus Genetics ( (IRD) ) has shared an update.
On December 17, 2025, Viatris Inc., the commercialization partner for Phentolamine Ophthalmic Solution 0.75% (Phentolamine), filed a supplemental New Drug Application with the U.S. Food and Drug Administration seeking approval of Phentolamine as a treatment for presbyopia. The submission, backed by positive efficacy, safety, and durability data from the VEGA-3 Phase 3 trial that confirmed earlier VEGA-2 results, marks a key regulatory step that could expand Phentolamine’s commercial prospects in the presbyopia market, though there remains uncertainty over if and when the FDA will accept and review the application.
The most recent analyst rating on (IRD) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Opus Genetics stock, see the IRD Stock Forecast page.
Spark’s Take on IRD Stock
According to Spark, TipRanks’ AI Analyst, IRD is a Neutral.
Opus Genetics faces significant financial challenges, with declining revenues and persistent losses undermining its financial stability. The technical indicators suggest a bearish trend, while the negative corporate event further highlights financing difficulties. These factors contribute to a low overall score, indicating a high-risk investment with uncertain prospects.
To see Spark’s full report on IRD stock, click here.
More about Opus Genetics
Average Trading Volume: 527,114
Technical Sentiment Signal: Buy
Current Market Cap: $139.3M
See more data about IRD stock on TipRanks’ Stock Analysis page.